Patents by Inventor Lars Thim

Lars Thim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20180179262
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 28, 2018
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Hjortnaes Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20160318991
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Stabilized Factor VIII Variants
    Publication number: 20160264645
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Conjugated Factor VIII Molecules
    Publication number: 20160222086
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half-life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 4, 2016
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20160207977
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 10, 2014
    Publication date: July 21, 2016
    Inventors: Ole Hvilsted Olsen, Marianne Hjortnaes Kjalke, Maj Petersen, Lars Thim, Kirstine Roepstorff, Jens Jacob Hansen, Jesper Haaning, Frederik Rode, Ditte Maria Karpf, Christian Rischel, Gert Bolt
  • Pharmaceutical Composition Suitable for Treatment of Haemophilia
    Publication number: 20160120954
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 5, 2016
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • Conjugated factor VIII molecules
    Patent number: 9150848
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Novo Nordisk A/s
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Compounds suitable for treatment of haemophilia
    Patent number: 9125890
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 8, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20150080309
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens J. Hansen
  • Pharmaceutical Composition Suitable for Treatment of Haemophilia
    Publication number: 20150045303
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • CONJUGATED FACTOR VIII MOLECULES
    Publication number: 20140242057
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA
    Publication number: 20140018297
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 16, 2014
    Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Conjugated factor VIII molecules
    Patent number: 8536126
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Conjugated Factor VIII Molecules
    Publication number: 20130189239
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: February 26, 2009
    Publication date: July 25, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
  • STABILIZED FACTOR VIII VARIANTS
    Publication number: 20130183280
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 18, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Purification of factor VIII using a mixed-mode or multimodal resin
    Patent number: 8399620
    Abstract: A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: March 19, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Susanne Bang, Lars Thim, Johan Karlsson
  • Use of GLP-1 Peptides
    Publication number: 20110028391
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: October 15, 2010
    Publication date: February 3, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Purification of Factor VIII Using a Mixed-Mode or Multimodal Resin
    Publication number: 20100204452
    Abstract: A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII.
    Type: Application
    Filed: July 11, 2008
    Publication date: August 12, 2010
    Applicant: Novo Nordisk Health Care AG
    Inventors: Susanne Bang, Lars Thim, Johan Karlsson
  • MUCOSAL REPAIR BY TFF DIMER PEPTIDES
    Publication number: 20100184644
    Abstract: The present invention relates to the use of trefoil factor 1 (TFF1) and trefoil factor 3 (TFF3) dimers and a pharmaceutical composition comprising TFF dimers for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and large intestine, colon) the respiratory passages, the eye, the urinary system (including the bladder) and the cervis uteri.
    Type: Application
    Filed: June 18, 2009
    Publication date: July 22, 2010
    Inventors: Lars Thim, Steen Seier Poulsen
  • Use of GLP-1 Peptides
    Publication number: 20100113363
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: January 4, 2010
    Publication date: May 6, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff